Targeting the IL-6R–STAT6 axis and Notch4 signaling has demonstrated preclinical efficacy in suppressing airway inflammation and remodeling in asthma models, with early clinical observations supporting IL-6R blockade in asthma patients (85–87). This evidence concerns the gene NOTCH4 and asthma.